Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

NCT07217184

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Grand Rapids, Michigan, United States
  • GSK Investigational Site Madison, Wisconsin, United States
View all 19 locations
View Trial Details
Active, Not Recruiting

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01562405

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Emory University Atlanta, Georgia, United States
  • Massachusetts General Hosptial Boston, Massachusetts, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

NCT06253663

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Chiba University Hospital Chiba, Japan
  • Kyushu University Hospital Fukuoka, Japan
  • Hokkaido University Hospital Hokkaido, Japan
  • Kyoto University Hospital Kyoto, Japan
View Trial Details
Active, Not Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

NCT07217119

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Madison, Wisconsin, United States
  • GSK Investigational Site Fitzroy, Victoria, Australia
  • GSK Investigational Site Melbourne, Victoria, Australia
View Trial Details
Active, Not Recruiting

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

NCT04509700

Conditions
B-cell Malignancies, Bone Marrow Diseases, Hematologic Diseases, +10 more
Locations
  • Uab Comprehensive Cancer Center Birmingham, Alabama, United States
  • University of Alabama At Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Rochester Phoenix, Arizona, United States
  • University of Arizona Cancer Center-Out Pt. Tucson, Arizona, United States
View all 105 locations
View Trial Details
Active, Not Recruiting

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

NCT04161248

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • BCCA - Vancouver Vancouver, British Columbia, Canada
  • Kingston Health Sciences Centre Kingston, Ontario, Canada
  • University Health Network Toronto, Ontario, Canada
  • The Jewish General Hospital Montreal, Quebec, Canada
View Trial Details
Active, Not Recruiting

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

NCT02553460

Conditions
Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
  • Children's Hospital and Clinics of Minnesota Minneapolis, Minnesota, United States
View all 15 locations
View Trial Details

Related conditions